AstraZeneca Net Worth 2010-2023 | AZN

Interactive chart of historical net worth (market cap) for AstraZeneca (AZN) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. AstraZeneca net worth as of May 10, 2024 is $240.63B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $240.625B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $733.285B 105.98
Novo Nordisk (NVO) Denmark $577.366B 44.37
Johnson & Johnson (JNJ) United States $360.641B 14.33
Merck (MRK) United States $329.847B 60.01
AbbVie (ABBV) United States $283.245B 14.64
Novartis AG (NVS) Switzerland $204.829B 14.52
Pfizer (PFE) United States $159.685B 19.84
Sanofi (SNY) $123.167B 11.62
Innoviva (INVA) United States $0.967B 6.71